{"entity":{"id":"indupro-therapeutics","kind":"company","name":"InduPro Therapeutics","aka":["InduPro"],"tldr":"InduPro Therapeutics maps which proteins sit side by side on the surface of cancer cells and designs two-armed antibody-drug conjugates that bind such a pair. Its first medicine, for lung and other squamous cancers, entered a phase 1 trial in 2026.","summary":"InduPro Therapeutics, formed in 2022 with offices in Seattle and Cambridge, Massachusetts, uses a proximity-guided discovery platform to find Tumour Associated Proximity Antigens (TAPAs), proteins that sit next to a known target on cancer cells, and builds bispecific antibody-drug conjugates against the pair. Its lead IDP-001 is a bispecific ADC against EGFR and TAPA-E1; on 12 August 2026 the company reported the first patient dosed in a phase 1 study (NCT07602842) in advanced or metastatic squamous or non-squamous non-small cell lung cancer and other squamous solid tumours. Further programmes listed include IDP-012 (EGFR x TAPA-E1 with a topoisomerase 1 inhibitor payload), IDP-004 (MET x TAPA-M1) and PD-1 bispecifics for immuno-oncology and autoimmunity. Financing comprises an USD 85 million Series A in June 2024 co-led by The Column Group and Vida Ventures and a USD 77 million Series B in August 2026 led by The Column Group, with Sanofi and Eli Lilly among new investors; Lilly also signed an oncology collaboration in January 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.induprotx.com/"},{"label":"USD 85 million Series A, June 2024","url":"https://www.biospace.com/indupro-announces-85-million-series-a-financing-appoints-prakash-raman-ph-d-as-ceo-to-advance-next-generation-proximity-based-protein-therapeutics-for-the-treatment-of-cancer-and-autoimmune-diseases"},{"label":"USD 77 million Series B and first patient dosed with IDP-001, August 2026","url":"https://www.induprotx.com/news/indupro-closes-77-million-series-b-financing-and-doses-first-patient-in-phase-1-study-of-lead-oncology-program-idp-001/"},{"label":"Pipeline","url":"https://www.induprotx.com/pipeline/"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["adcs"],"technologies":["bispecific-adc","adc","bispecific-antibody"],"targets":["egfr","met"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07602842"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["TAPA-E1 and TAPA-M1 are the company's own names for undisclosed partner antigens. The Endpoints figure of up to USD 950 million for the Lilly collaboration was seen only as a headline and is not stated here as a fact."],"hq":"Seattle, WA","country":"US","companyType":"biotech","website":"https://www.induprotx.com/","founded":2022,"stage":"startup","investors":["vida-ventures"],"funding":[{"round":"Series A","year":2024,"amountUsd":85000000,"source":"https://www.biospace.com/indupro-announces-85-million-series-a-financing-appoints-prakash-raman-ph-d-as-ceo-to-advance-next-generation-proximity-based-protein-therapeutics-for-the-treatment-of-cancer-and-autoimmune-diseases","note":"Co-led by The Column Group and Vida Ventures"},{"round":"Series B","year":2026,"amountUsd":77000000,"source":"https://www.induprotx.com/news/indupro-closes-77-million-series-b-financing-and-doses-first-patient-in-phase-1-study-of-lead-oncology-program-idp-001/","note":"Led by The Column Group"}]},"route":"/companies/indupro-therapeutics/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"trial":[{"id":"nct07602842","kind":"trial","name":"A Study of IDP-001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct07602842/"}],"company":[{"id":"vida-ventures","kind":"company","name":"Vida Ventures","route":"/companies/vida-ventures/"}]}}